Researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding. 

The study focused on B-cell lymphoma 6 (BCL6), a protein implicated in several cancers. Using advanced computational techniques, the team showed how subtle changes in drug molecules can disrupt or stabilise water networks in the protein’s binding site, dramatically affecting drug potency. 

The team say this method could be used by researchers worldwide to actively guide the design of new drugs, improving both their potency and their selectivity. In the longer term, this could increase the availability of effective cancer medications that are kinder on the body. 

The study was led by researchers at The Institute of Cancer Research, London. The Medical Research Council provided funding in the form of a grant, which was partly supported by AstraZeneca. 

“Water networks are like invisible scaffolding,” said first author Daniella Hares, a PhD student in the Division of Cancer Therapeutics at The Institute of Cancer Research (ICR). “They hold everything together, and if you remove one piece, the whole structure can shift. Our simulations help us see how that scaffolding behaves when we tweak a drug molecule.” 

Computational modelling

The researchers used two powerful computational methods – Grand Canonical Monte Carlo (GCMC) simulations and alchemical free energy calculations – that model how water molecules behave and how changes in drug structure affect binding energy. 

They focused on four BCL6 inhibitors developed in earlier ICR-led research, each of which was designed to grow into a water-filled subpocket of the protein. These compounds sequentially displaced up to three water molecules, resulting in a 50-fold increase in potency. 

To understand why, using GCMC, the team simulated how water molecules occupied the subpocket in the presence of each compound. The simulations reproduced 94% of the water sites observed in crystal structures, even when starting from different protein conformations. This suggests that GCMC could be a reliable tool early in drug development, before experimental data are available. 

The study also compared GCMC with faster solvent analysis methods, such as SZMAP and 3D-RISM. The team found that GCMC provided a more nuanced picture, with the other techniques often failing to capture the cooperative effects between water molecules. 

Looking ahead, the researchers plan to apply their methods to other drug targets with complex water networks. They believe that integrating GCMC into standard drug design workflows could lead to faster, more efficient development of cancer therapies. 

Senior author Professor Swen Hoelder, Group Leader of the Medicinal Chemistry 4 Group (including Analytical Chemistry) at the ICR, said: “The implications for drug discovery are significant. Traditionally, optimising a drug to interact with water networks requires multiple rounds of synthesis and testing – a process that can take years. By using GCMC and alchemical calculations, we can predict which modifications are likely to succeed before entering the lab.”

Diana Turner, Deputy Editor, DDW